CooperCompanies Q3 adjusted EPS beats estimates
Overview
CooperCompanies fiscal Q3 revenue rises 6% yr/yr to $1,060.3 mln, meets expectations, per LSEG data
Non-GAAP diluted EPS up 15% to $1.10, beating analyst expectations, per LSEG data
Co repurchased $52.1 mln of shares, $163.6 mln remains in buyback program
Outlook
CooperCompanies raises fiscal 2025 non-GAAP EPS guidance to $4.08 - $4.12
Company expects Q4 2025 revenue of $1,049 - $1,069 mln
CVI revenue forecasted at $700- $713 mln for Q4 2025
CSI revenue projected at $350 - $356 mln for Q4 2025
Result Drivers
PRODUCT LINE EXIT - CooperSurgical's gross and operating margins were impacted by a product line exit, reducing GAAP margins
EFFICIENCY GAINS - Non-GAAP gross margin improved by 70 basis points due to efficiency gains and favorable foreign exchange
REVENUE GROWTH - CooperVision revenue grew 6% driven by strong performance in Toric and multifocal lenses
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | In-line | $1.06 bln | $1.06 bln (14 Analysts) |
Q3 Adjusted EPS | Beat | $1.1 | $1.07 (15 Analysts) |
Q3 EPS |
| $0.49 |
|
Q3 Gross Margin |
| 65.0% |
|
Q3 EBIT Margin |
| 17.0% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Cooper Companies Inc is $94.00, about 21.6% above its August 26 closing price of $73.66
Press Release: ID:nGNX6sfVJC
Recommended Articles
